CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers
University of Geneva · University of Bern · +15 more institutions
Abstract
Tumor microenvironments (TMEs) influence cancer progression but are complex and often differ between patients. Considering that microenvironment variations may reveal rules governing intratumoral cellular programs and disease outcome, we focused on tumor-to-tumor variation to examine 52 head and neck squamous cell carcinomas. We found that macrophage polarity—defined by CXCL9 and SPP1 (CS) expression but not by conventional M1 and M2 markers—had a noticeably strong prognostic association. CS macrophage polarity also identified a highly coordinated network of either pro- or antitumor variables, which involved each tumor-associated cell type and was spatially organized. We extended these findings to other cancer…
Citation impact
- FWCI
- 93.62
- Percentile
- 100%
- References
- 62
Authors
33- RBRuben BillCorresponding
University of Geneva, University of Bern, Harvard University, University Hospital of Bern, Massachusetts General Hospital, Swiss Cancer Center Léman, Center for Systems Biology
- PWPratyaksha WirapatiCorresponding
University of Geneva, Swiss Cancer Center Léman
- MMMarius Messemaker
Harvard University, The Netherlands Cancer Institute, Massachusetts General Hospital, Center for Systems Biology
- WRWhijae Roh
Broad Institute
- BZBéatrice Zitti
University of Geneva, Swiss Cancer Center Léman
Topics & keywords
- Polarity (international relations)
- Macrophage
- Tumor microenvironment
- Cancer
- Biology
- Cancer research
- Cell
- Medicine
- Good health and well-being
Funding
- NSNational Science Foundation
- BSBristol-Myers Squibb
- AAstraZeneca
- SSanofi
- LILudwig Institute for Cancer Research
- SNSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ForschungAwards: P5R5PM_203164, P400PM_183852
- SDStudienstiftung des Deutschen Volkes
- FIFondation ISREC
- NINational Institutes of HealthAwards: P01-CA240239, R01-CA218579
- GGenentech
- PPharmacyclics